On February 23, the FDA approved Shire and New River’s Vyvanse (lisdexamfetamine dimesylate) for the treatment of ADHD in children. Vyvanse is the molecule dextroamphetamine (trade names Dexedrine and Dextrostat) attached to the amino acid lysine.
Read More
Every month seems to bring a new FDA advisory or an alarming research finding about the use of medications in pregnancy. In this article, we update you on what we consider to be the most important developments over the past couple of years.
Read More
Over the last several years, we’ve all seen many FDA warnings and cautionary letters from drug companies about the effects of psychotropics in pregnancy. As a result, it’s easy to become a little skittish about prescribing any medication for pregnant women.
Read More
Dr. Brizendine, as the director of the UCSF Women’s Mood and Hormone Clinic, you receive many referrals of women who are having difficulty with menopause. What are the typical problems that women have during this period?
Read More
Provigil (modafinil) is FDA approved for excessive sleepiness due to various causes. An ADHD indication was rejected because of its possible association with a single case of Stevens-Johnson syndrome.
Read More
The combination of Effexor (venlafaxine) and Remeron (mirtazapine) has been dubbed “California Rocket Fuel” by Stephen Stahl (see page 290 of his Essential Psychopharmacology, 2nd Edition) because of the multiple ways the combination boosts various neurotransmitter systems.
Read More
A widely cited sequence of reactions following the death of a loved one includes: disbelief, yearning (for the loved one’s return), anger, depression/mourning, and acceptance. Researchers conducted a study aimed at empirically assessing whether these stages actually occur and, if so, in what order.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
